TECNOTREE
19.9.2022 11:01:39 CEST | Business Wire | Press release
Tecnotree, a leading global Digital Transformation Partner for the Telecom Industry, is the first non-telco to be certified for real-world open API implementation on the leader board for TM Forum Open API Conformance. The certifications were carried out jointly with MTN in live operations within the MTN environment and demonstrated the successful implementation of Open APIs in commercial products and real-world deployments. Alignment to industry standards and best practices have been a part of Tecnotree’s DNA and its Digital Transformation strategy and proves Tecnotree’s commitment to industry standards, customers, and partner ecosystems. This landmark achievement makes Tecnotree the first Digital Platform Company among a list of CSPs like Verizon, Bell, and JIO, for certified real-world open API implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005054/en/
Tecnotree is the First Digital Platform Company in the World to be Certified for Real-World Open API Implementation by TM Forum (Photo: Business Wire)
Tecnotree’s Digital Platform powered with Open APIs using Open Digital Architecture enables quick and flexible integration to transform telecom business and operation models that extends beyond connectivity to monetise platform-based business models and partner ecosystems across verticals.
“We congratulate Tecnotree for being the first non-telco to achieve real-world certification for Open APIs deployed in live operation with MTN,” commented George Glass, CTO of TM Forum. “This is a path-breaking move by a software solutions provider and reaffirms Tecnotree’s commitment to open standards and their investment in next-generation product modernization. Tecnotree has been a great supporter of TM Forum’s work and is demonstrating the business value of Open APIs in enabling digital transformation for their customers.”
Monzer Ali, CTIO of MTN Uganda commented, “MTN and Tecnotree have been at the forefront of aligning with TM Forum frameworks (TAM, SID, Open APIs, eTOM) in our digital transformation journey. Tecnotree Digital BSS Suite is TMF ODA’s component-based architecture and is fully cloud-enabled, having an orchestration of micro-services capability that allows us to provide not only connectivity services for our subscribers but also digital services from adjacent industries, thus truly helping us monetize the power of 5G.”
Padma Ravichander, CEO of Tecnotree Corporation said, “This recognition is a true testimony of our journey as a pioneer in TM Forum’s Open API certification. Real-world Open API conformance and certification for Tecnotree is our commitment towards our customers to help them unlock and monetize the power of 5G with a range of digital products and services. These solutions can be provided to their customers, with seamless connectivity, speed, agility, and interoperability, on our Tecnotree Digital BSS platform. Our platform further enables operators to partner with the industry’s best ecosystem players to monetize B2B and B2B2X non-telco offerings by leveraging 5G for new digital multi-experiences.”
TM Forum Open API suite was developed in collaboration to drive IT agility, and digital business transformation. The certification recognizes how well your industry solutions, business processes, or open APIs align within the industry standards. They unlock a range of growth opportunities by providing exposure to new products and services while reducing cost and time to market. A large number of major global operators and vendors use the TM Forum Open API conformance, and the APIs are deployed all over the world.
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is the first company in the world to be Platinum Certified by TM Forum Open API standards, and our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree digital platform products and services today serve over 1 Billion Subscribers globally in over 70 countries. Tecnotree is listed on Helsinki Nasdaq (TEM1V).
For more information, please visit www.tecnotree.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005054/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom